These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1044 related articles for article (PubMed ID: 23729001)

  • 1. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B colloidal dispersion.
    Patel R
    Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment and amphotericin B formulations in patients with invasive fungal infections.
    Saliba F; Dupont B
    Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New lipid formulations of amphotericin B. Review of the literature].
    Andrès E; Tiphine M; Letscher-Bru V; Herbrecht R
    Rev Med Interne; 2001 Feb; 22(2):141-50. PubMed ID: 11234672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B lipid complex.
    Rapp RP; Gubbins PO; Evans ME
    Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
    Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
    Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP; Garey KW; Danziger LH
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B lipid complex for the treatment of invasive fungal infections.
    Linden PK
    Expert Opin Pharmacother; 2003 Nov; 4(11):2099-110. PubMed ID: 14596663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing efficacy of amphotericin B through nanomodification.
    Vyas SP; Gupta S
    Int J Nanomedicine; 2006; 1(4):417-32. PubMed ID: 17722276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the lipid formulations of amphotericin B.
    Dupont B
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.
    Barrett JP; Vardulaki KA; Conlon C; Cooke J; Daza-Ramirez P; Evans EG; Hawkey PM; Herbrecht R; Marks DI; Moraleda JM; Park GR; Senn SJ; Viscoli C;
    Clin Ther; 2003 May; 25(5):1295-320. PubMed ID: 12867214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipid formulations of amphotericin B in the management of invasive fungal infections].
    Fohrer C; Nivoix Y; Moulin JC; Marçais A; Herbrecht R
    Therapie; 2006; 61(3):235-42. PubMed ID: 16989124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.